Dyne Therapeutics Inc (DYN) - Net Assets
Based on the latest financial reports, Dyne Therapeutics Inc (DYN) has net assets worth $972.13 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.19 Billion) and total liabilities ($214.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Dyne Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $972.13 Million |
| % of Total Assets | 81.9% |
| Annual Growth Rate | -8.19% |
| 5-Year Change | 164.02% |
| 10-Year Change | -52.39% |
| Growth Volatility | 563.53 |
Dyne Therapeutics Inc - Net Assets Trend (2007–2025)
This chart illustrates how Dyne Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Dyne Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual net assets of Dyne Therapeutics Inc from 2007 to 2025. For live valuation and market cap data, see Dyne Therapeutics Inc (DYN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $972.13 Million | +54.35% |
| 2024-12-31 | $629.84 Million | +589.92% |
| 2023-12-31 | $91.29 Million | -63.83% |
| 2022-12-31 | $252.36 Million | -31.46% |
| 2021-12-31 | $368.20 Million | +7.54% |
| 2020-12-31 | $342.37 Million | +2339.21% |
| 2019-12-31 | $14.04 Million | +387.68% |
| 2018-12-31 | $-4.88 Million | -100.26% |
| 2017-12-31 | $1.90 Billion | -6.90% |
| 2016-12-31 | $2.04 Billion | -30.09% |
| 2015-12-31 | $2.92 Billion | -3.37% |
| 2014-12-31 | $3.02 Billion | +36.79% |
| 2013-12-31 | $2.21 Billion | -11.71% |
| 2012-12-31 | $2.50 Billion | +125.09% |
| 2011-12-31 | $1.11 Billion | -59.50% |
| 2010-12-31 | $2.75 Billion | -7.82% |
| 2009-12-31 | $2.98 Billion | -33.58% |
| 2008-12-31 | $4.49 Billion | -0.97% |
| 2007-12-31 | $4.53 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dyne Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 139614200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.00K | 0.00% |
| Other Components | $2.37 Billion | 243.62% |
| Total Equity | $972.13 Million | 100.00% |
Dyne Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Dyne Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanxiang Advanced Materials
SHG:603663
|
$2.87 Billion |
|
American Eagle Outfitters Inc
NYSE:AEO
|
$2.87 Billion |
|
Q2 Holdings
NYSE:QTWO
|
$2.87 Billion |
|
HC Semitek Corp
SHE:300323
|
$2.87 Billion |
|
Koza Altin Isletmeleri AS
IS:KOZAL
|
$2.87 Billion |
|
Liechtensteinische Landesbank AG
SW:LLBN
|
$2.87 Billion |
|
CECEP Solar Energy Co Ltd
SHE:000591
|
$2.87 Billion |
|
Fortuna Silver Mines Inc
TO:FVI
|
$2.86 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dyne Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 629,838,000 to 972,129,000, a change of 342,291,000 (54.3%).
- Net loss of 446,214,000 reduced equity.
- New share issuances of 734,610,000 increased equity.
- Other comprehensive income decreased equity by 6,000.
- Other factors increased equity by 53,901,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-446.21 Million | -45.9% |
| Share Issuances | $734.61 Million | +75.57% |
| Other Comprehensive Income | $-6.00K | -0.0% |
| Other Changes | $53.90 Million | +5.54% |
| Total Change | $- | 54.35% |
Book Value vs Market Value Analysis
This analysis compares Dyne Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.02x to 2.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $4.32 | $17.39 | x |
| 2008-12-31 | $5.19 | $17.39 | x |
| 2009-12-31 | $2.87 | $17.39 | x |
| 2010-12-31 | $22.69 | $17.39 | x |
| 2011-12-31 | $9.11 | $17.39 | x |
| 2012-12-31 | $25.03 | $17.39 | x |
| 2013-12-31 | $22.10 | $17.39 | x |
| 2014-12-31 | $23.99 | $17.39 | x |
| 2015-12-31 | $23.18 | $17.39 | x |
| 2016-12-31 | $15.83 | $17.39 | x |
| 2017-12-31 | $11.73 | $17.39 | x |
| 2018-12-31 | $-0.47 | $17.39 | x |
| 2019-12-31 | $0.31 | $17.39 | x |
| 2020-12-31 | $7.24 | $17.39 | x |
| 2021-12-31 | $7.23 | $17.39 | x |
| 2022-12-31 | $4.86 | $17.39 | x |
| 2023-12-31 | $1.53 | $17.39 | x |
| 2024-12-31 | $6.69 | $17.39 | x |
| 2025-12-31 | $7.57 | $17.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dyne Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-45.90%) is below the historical average (-43.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 5.86% | 8.51% | 0.23x | 2.93x | $-186.60 Million |
| 2008 | 3.85% | 4.90% | 0.25x | 3.15x | $-277.50 Million |
| 2009 | -43.49% | -51.13% | 0.23x | 3.77x | $-1.55 Billion |
| 2010 | -8.52% | -10.07% | 0.23x | 3.65x | $-508.60 Million |
| 2011 | -147.93% | -103.79% | 0.38x | 3.71x | $-1.76 Billion |
| 2012 | 3.48% | 2900.00% | 0.00x | 1.81x | $-163.30 Million |
| 2013 | -16.11% | -11866.67% | 0.00x | 2.39x | $-577.00 Million |
| 2014 | -2.22% | -4.57% | 0.13x | 3.72x | $-369.30 Million |
| 2015 | 1.71% | 5.94% | 0.07x | 3.95x | $-242.10 Million |
| 2016 | -60.72% | -90.78% | 0.10x | 6.39x | $-1.44 Billion |
| 2017 | 4.00% | 15.02% | 0.04x | 6.19x | $-114.10 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.32 Million |
| 2019 | -96.44% | 0.00% | 0.00x | 1.17x | $-14.94 Million |
| 2020 | -17.16% | 0.00% | 0.00x | 1.03x | $-92.97 Million |
| 2021 | -40.55% | 0.00% | 0.00x | 1.16x | $-186.11 Million |
| 2022 | -65.48% | 0.00% | 0.00x | 1.21x | $-190.47 Million |
| 2023 | -258.44% | 0.00% | 0.00x | 1.81x | $-245.07 Million |
| 2024 | -50.40% | 0.00% | 0.00x | 1.10x | $-380.40 Million |
| 2025 | -45.90% | 0.00% | 0.00x | 1.22x | $-543.43 Million |
Industry Comparison
This section compares Dyne Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dyne Therapeutics Inc (DYN) | $972.13 Million | 5.86% | 0.22x | $2.87 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more